Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Imunoterapija : nova zdravila, drugačni sopojavi
Authors:ID Ovčariček, Tanja (Author)
Files:.pdf PDF - Presentation file, download (94,71 KB)
MD5: 07BA677BAB7A48AC4704776D61D4728B
 
Language:Slovenian
Typology:1.04 - Professional Article
Organization:Logo OI - Institute of Oncology
Abstract:Imunoterapija je v zadnjih letih postala eden izmed pomembnih načinov sistemskega zdravljenja bolnikov z rakom. Priča smo bili različnim imunskim strategijam, med temi je tudi inhibicija kontrolnih točk. Zdravila proti CTLA-4, PD-1 in PD-L1 so protitelesa proti zaviralcem kontrolnih točk, ki lahko povišajo imunsko aktivnost proti rakavim celicam in tako ojačajo imunski odgovor proti raku. Večja uporaba teh zdravil pa je privedla do pojava posebne vrste imunsko pogojenih neželenih učinkov. Ti se najpogosteje izrazijo na koži, črevesju, žlezah z notranjim izločanjem, pljučih in mišično-skeletnem sistemu, lahko pa je prizadet kateri koli organ. Večina imunsko pogojenih neželenih učinkov je blagih do zmernih, v literaturi pa obstajajo poročila o hudih in življenje ogrožajočih. Pomembna je njihova zgodnja prepoznava in zdravljenje, kakor tudi multidisciplinaren pristop, da preprečimo resne zaplete.
Keywords:imunoterapija, zaviralci kontrolnih točk, neželeni učinki
Publication status:Published
Publication version:Version of Record
Year of publishing:2018
Number of pages:str. 18-22
Numbering:Letn. 22, št. 1
PID:20.500.12556/DiRROS-9223 New window
UDC:616-006
ISSN on article:1408-1741
DOI:10.25670/oi2018-003on New window
COBISS.SI-ID:2990715 New window
Copyright:by Authors
Publication date in DiRROS:26.10.2018
Views:4438
Downloads:971
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Onkologija
Shortened title:Onkologija
Publisher:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:26.10.2018

Secondary language

Language:English
Title:Imunotherapy : new drugs, different adverse events
Abstract:Over the past years, immunotherapy has become an important systemic treatment strategy for cancer patients. We have seen multiple different strategies, and checkpoint blockade is one them. Anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death-1 (PD-1), and programmed death-ligand 1 (PD-L1) are antibodies against checkpoint inhibitors that can increase immune activity against cancer, thus making the immune system stronger against cancer cells. However, the increasing use of these agents has exposed a discrete group of immune-related adverse events (irAEs). Skin, gut, endocrine, lung, and musculoskeletal irAEs are the most common, although every organ can be affected. The majority of irAEs are mild to moderate in severity, however, serious and life-threatening irAEs are reported in literature. Early detection and treatment of irAEs is important, and a multidisciplinary approach is sometimes needed to prevent serious consequences.
Keywords:immunotherapy, checkpoints inhibitors, adverse events


Archive

niGradiv

Back